Vyndamax
Active Ingredient(s): TafamidisFDA Approved: * May 3, 2019
Pharm Company: * FOLDRX PHARMS
Category: Genetic Disorders
Tafamidis, sold under the brand names Vyndaqel and Vyndamax,[3] is a medication used to delay disease progression in adults with certain forms of transthyretin amyloidosis. It can be used to treat both hereditary forms, familial amyloid cardiomyopathy and familial amyloid polyneuropathy, as well as wild-type transthyretin amyloidosis, which formerly was called senile systemic amyloidosis. It works by stabilizing the quaternary structure of the protein transthyretin. In people ... [wikipedia]
* May have multiple approval dates, manufacturers, or labelers.Dosage List
Vyndamax 61 mg Oral Capsule, Liquid Filled
NDC: 0069-8730
Labeler:
Pfizer Laboratories Div Pfizer Inc